Дмитрий Александрович Астапов
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Дмитрий Александрович Астапов has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Vladimirovich Bogachev-Prokophiev
Meshalkin National Medical Research Center
6 shared publications - Ravil M. Sharifulin
Meshalkin National Medical Research Center
5 shared publications - Alexander V. Afanasyev
Meshalkin National Medical Research Center Novosibirsk Russian Federation
4 shared publications - Alexei N. Pivkin
Meshalkin National Medical Research Center
4 shared publications - Marina A. Ovchinnikova
Meshalkin National Medical Research Center
3 shared publications - Михаил Александрович Овчаров
Meshalkin National Medical Research Center
3 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 29 (4) , 6-12
Preclinical study of the efficacy of the VVF34 composition for chemical myocardial ablation
Background: Ventricular arrhythmias (VA) remain a leading cause of cardiovascular mortality. Existing ablation methods, including radiofrequency ablation (RFA), have limitations related to the depth and homogeneity of the lesion created. Objective: The objective of this study was to experimentally assess the efficacy of a new method on controlled chemical myocardial ablation using the VVF34 composition. Methods: The study was conducted on rats (n = 60) and minipigs (n = 6). The histological dynamics and dose-dependent fibrosis formation in response to intramuscular administration of VVF34 (0.1; 0.2 and 0.3 ml) were studied in rats. Intramyocardial injection under fluoroscopic guidance using a Myostar catheter was tested in minipigs, and the safety of the procedure was assessed using echocardiography and electrocardiography. Results: VVF34 has been shown to induce dose-dependent formation of a sharply marginated zone. A low dose (0.1 ml) proved to be optimal, resulting in the formation of dense fibrosis with minimal inflammation, while elevating the dose caused destructive necrosis. To create extended ablation lines, it was appropriate to use a series of injections spaced at least 3 mm. The intramyocardial injection procedure was safe, did not have a proarrhythmic effect, and did not impair cardiac contractility. Conclusion: Chemical ablation with VVF34 composition is a promising alternative to existing approaches and enables to create controlled homogeneous deep fibrotic lesions, opening up new possibilities for the treatment of resistant ventricular arrhythmias.
- 21 January 2026
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 29 (4) , 6-12
Open AccessPreclinical study of the efficacy of the VVF34 composition for chemical myocardial ablation
Background: Ventricular arrhythmias (VA) remain a leading cause of cardiovascular mortality. Existing ablation methods, including radiofrequency ablation (RFA), have limitations related to the depth and homogeneity of the lesion created. Objective: The objective of this study was to experimentally assess the efficacy of a new method on controlled chemical myocardial ablation using the VVF34 composition. Methods: The study was conducted on rats (n = 60) and minipigs (n = 6). The histological dynamics and dose-dependent fibrosis formation in response to intramuscular administration of VVF34 (0.1; 0.2 and 0.3 ml) were studied in rats. Intramyocardial injection under fluoroscopic guidance using a Myostar catheter was tested in minipigs, and the safety of the procedure was assessed using echocardiography and electrocardiography. Results: VVF34 has been shown to induce dose-dependent formation of a sharply marginated zone. A low dose (0.1 ml) proved to be optimal, resulting in the formation of dense fibrosis with minimal inflammation, while elevating the dose caused destructive necrosis. To create extended ablation lines, it was appropriate to use a series of injections spaced at least 3 mm. The intramyocardial injection procedure was safe, did not have a proarrhythmic effect, and did not impair cardiac contractility. Conclusion: Chemical ablation with VVF34 composition is a promising alternative to existing approaches and enables to create controlled homogeneous deep fibrotic lesions, opening up new possibilities for the treatment of resistant ventricular arrhythmias.
- Open Access
- 30 June 2025
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 10 (2) , 96-104
Analysis of results to optimize anticoagulant therapy in patients who underwent mechanical heart valve replacement: a pilot singlecenter controlled study
Aim. This study aims to conduct a comparative analysis of anticoagulant-related complications and clinical outcomes in patients with mechanical aortic valve prostheses who are on long-term warfarin therapy. The analysis will focus on two groups: those maintained at therapeutic INR values (3 ± 0.5) and those maintained at reduced INR values (2 ± 0.5). Material and methods. The analysis of a prospective, randomized, single-center study included 80 patients (56% men and 44% women) who underwent mechanical aortic valve replacement between March 2020 and September 2022. The observation period lasted 12 months, with an average age of 59 years (range: 50-63). The primary endpoint was a composite outcome measured over 12 months, consisting of death, symptomatic bleeding, thrombosis, and thromboembolism. Patients were enrolled based on the following inclusion criteria: mechanical prosthesis in the aortic position implanted more than three months prior, age over 18 at the time of inclusion, and provision of written informed consent. Exclusion criteria included multivalvular prosthetics, history of cardiac cavity thrombosis, left ventricular ejection fraction of less than 30%, atrial fibrillation/flutter, pregnancy or plans for pregnancy during the study, patient refusal at any stage of the study, liver pathology (types B and C according to Child- Pugh), and severe renal failure (creatinine clearance Results. All participants (n = 80, 100%) completed the pilot study. Among the 40 patients in the study group, 6 (7.5%) experienced events related to the primary endpoint. The odds ratio for the primary endpoint at 12 months was 2.71 (p = 0.25). Additionally, the odds ratio for the primary endpoint at 18 months was calculated to be 3.35 (p = 0.155). Given the observed negative trend in the frequency of disabling events in the primary group, and despite the lack of statistically significant differences, the study was terminated at the pilot stage for ethical reasons. Conclusion. This study reveals a negative trend in the frequency of primary endpoint events among patients with reduced INR levels. Notably, the majority of these events consisted of ischemic strokes, which occurred in 5% of the study group. Consequently, the optimal target INR range for patients who have undergone heart valve replacement with mechanical prostheses remains inadequately defined
- 30 June 2025
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 10 (2) , 96-104
Open AccessAnalysis of results to optimize anticoagulant therapy in patients who underwent mechanical heart valve replacement: a pilot singlecenter controlled study
Aim. This study aims to conduct a comparative analysis of anticoagulant-related complications and clinical outcomes in patients with mechanical aortic valve prostheses who are on long-term warfarin therapy. The analysis will focus on two groups: those maintained at therapeutic INR values (3 ± 0.5) and those maintained at reduced INR values (2 ± 0.5). Material and methods. The analysis of a prospective, randomized, single-center study included 80 patients (56% men and 44% women) who underwent mechanical aortic valve replacement between March 2020 and September 2022. The observation period lasted 12 months, with an average age of 59 years (range: 50-63). The primary endpoint was a composite outcome measured over 12 months, consisting of death, symptomatic bleeding, thrombosis, and thromboembolism. Patients were enrolled based on the following inclusion criteria: mechanical prosthesis in the aortic position implanted more than three months prior, age over 18 at the time of inclusion, and provision of written informed consent. Exclusion criteria included multivalvular prosthetics, history of cardiac cavity thrombosis, left ventricular ejection fraction of less than 30%, atrial fibrillation/flutter, pregnancy or plans for pregnancy during the study, patient refusal at any stage of the study, liver pathology (types B and C according to Child- Pugh), and severe renal failure (creatinine clearance Results. All participants (n = 80, 100%) completed the pilot study. Among the 40 patients in the study group, 6 (7.5%) experienced events related to the primary endpoint. The odds ratio for the primary endpoint at 12 months was 2.71 (p = 0.25). Additionally, the odds ratio for the primary endpoint at 18 months was calculated to be 3.35 (p = 0.155). Given the observed negative trend in the frequency of disabling events in the primary group, and despite the lack of statistically significant differences, the study was terminated at the pilot stage for ethical reasons. Conclusion. This study reveals a negative trend in the frequency of primary endpoint events among patients with reduced INR levels. Notably, the majority of these events consisted of ischemic strokes, which occurred in 5% of the study group. Consequently, the optimal target INR range for patients who have undergone heart valve replacement with mechanical prostheses remains inadequately defined
- Open Access
- 20 June 2024
- Published by Vidar, Ltd. in Ultrasound & Functional Diagnostics
- No. 2,p. 10-29
Analysis of the significance of echocardiographic signs of right ventricular dysfunction for predicting the outcome of heart failure with reduced left ventricular ejection fraction
Objective: to determine the ultrasound signs of right heart dysfunction, which increase the prognostic value of the recommended parameters of left ventricular (LV) dysfunction in patients with heart failure with reduced ejection fraction (HFrEF). Materials and methods. The prospective study included 79 patients with HFrEF LV with clinical manifestations of chronic heart failure functional class III according to the New York Heart Association (HF NYHA Class III) in 52 patients (65.8%) and HF NYHA Class IV in 27 (34.1%). The primary end point was death during a follow-up period of up to 3 years while waiting for heart transplantation. Results. Overall mortality was 33 patients (41.7%), 17 (21.5%) during the 1st year of follow-up. Regression analysis revealed the following independent ultrasound predictors of poor prognosis: LV ejection fraction on 3D-echocardiography (3DE LVEF), p = 0.014; global longitudinal strain of the LV (GLS LV), p = 0.010, and of the interventricular septum basal segment (IVSLS BS), p = 0.012; mean longitudinal strain of the basal segment of the right ventricle free wall (FWLS BS RV), p = 0.003. Changes in the configuration and dilatation of the LV cavity, an increase in LV end-diastolic pressure, impaired contractility, and strain of the LV myocardium can affect the function of the right ventricle (RV) through the common interventricular septum (IVS). Dilatation of the RV due to an increase in the end diastolic area (RV EDA) of more than 30 cm2 (p = 0.012) and end systolic area (RV ESA) of more than 25 cm2 (p = 0.001), an increase in the volume of the right atrium (3DE AKI) of more than 100 ml (p = 0.036), and a decrease in the % inspiratory collapse of the inferior vena cava (% IVC) less than 30% (p = 0.005) demonstrated a prognostic significance in the observed patients. A decrease in the deformation properties of the pancreas due to the longitudinal component and impaired strain of the basal segment makes a greater contribution to RV dysfunction (FWLS BS, % < -15% (p < 0.001)). Conclusions. RV dysfunction in patients with HFrEF is an unfavorable prognostic factor, independently associated with existing LV dysfunction. The most significant ultrasound sign for surveillance prediction of patients with LV HFrEF and RV dysfunction are indicators of ventricular myocardial deformation. Remodeling of the right chambers and dysfunction of the RV is a trigger for the separation of the RV and pulmonary artery, which ultimately leads to adverse outcomes.
- 20 June 2024
- Published by Vidar, Ltd. in Ultrasound & Functional Diagnostics
- No. 2,p. 10-29
Open AccessAnalysis of the significance of echocardiographic signs of right ventricular dysfunction for predicting the outcome of heart failure with reduced left ventricular ejection fraction
Objective: to determine the ultrasound signs of right heart dysfunction, which increase the prognostic value of the recommended parameters of left ventricular (LV) dysfunction in patients with heart failure with reduced ejection fraction (HFrEF). Materials and methods. The prospective study included 79 patients with HFrEF LV with clinical manifestations of chronic heart failure functional class III according to the New York Heart Association (HF NYHA Class III) in 52 patients (65.8%) and HF NYHA Class IV in 27 (34.1%). The primary end point was death during a follow-up period of up to 3 years while waiting for heart transplantation. Results. Overall mortality was 33 patients (41.7%), 17 (21.5%) during the 1st year of follow-up. Regression analysis revealed the following independent ultrasound predictors of poor prognosis: LV ejection fraction on 3D-echocardiography (3DE LVEF), p = 0.014; global longitudinal strain of the LV (GLS LV), p = 0.010, and of the interventricular septum basal segment (IVSLS BS), p = 0.012; mean longitudinal strain of the basal segment of the right ventricle free wall (FWLS BS RV), p = 0.003. Changes in the configuration and dilatation of the LV cavity, an increase in LV end-diastolic pressure, impaired contractility, and strain of the LV myocardium can affect the function of the right ventricle (RV) through the common interventricular septum (IVS). Dilatation of the RV due to an increase in the end diastolic area (RV EDA) of more than 30 cm2 (p = 0.012) and end systolic area (RV ESA) of more than 25 cm2 (p = 0.001), an increase in the volume of the right atrium (3DE AKI) of more than 100 ml (p = 0.036), and a decrease in the % inspiratory collapse of the inferior vena cava (% IVC) less than 30% (p = 0.005) demonstrated a prognostic significance in the observed patients. A decrease in the deformation properties of the pancreas due to the longitudinal component and impaired strain of the basal segment makes a greater contribution to RV dysfunction (FWLS BS, % < -15% (p < 0.001)). Conclusions. RV dysfunction in patients with HFrEF is an unfavorable prognostic factor, independently associated with existing LV dysfunction. The most significant ultrasound sign for surveillance prediction of patients with LV HFrEF and RV dysfunction are indicators of ventricular myocardial deformation. Remodeling of the right chambers and dysfunction of the RV is a trigger for the separation of the RV and pulmonary artery, which ultimately leads to adverse outcomes.
- Open Access
- 29 September 2023
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (3) , 131-142
Optimization of anticoagulant therapy in patients undergoing mechanical heart valve replacement
Acquired heart defects have a high prevalence among patients of different age groups and represent a significant social problem. To date, surgery remains the only effective option to treat acquired heart disease, and replacement of the dysfunctional heart valves frequently relies on mechanical prosthetic heart valves which implantation requires lifelong anticoagulant therapy with vitamin K antagonists and constant monitoring of international normalised ratio. However, the optimal target range for international normalised ratio values remains poorly defined. Optimisation of the approaches to anticoagulant therapy for this category of patients is becoming increasingly important. This paper highlights the main problems and possible solutions for patients who have undergone implantation of mechanical heart valves and need constant intake of vitamin K antagonists.
- 29 September 2023
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (3) , 131-142
Open AccessOptimization of anticoagulant therapy in patients undergoing mechanical heart valve replacement
Acquired heart defects have a high prevalence among patients of different age groups and represent a significant social problem. To date, surgery remains the only effective option to treat acquired heart disease, and replacement of the dysfunctional heart valves frequently relies on mechanical prosthetic heart valves which implantation requires lifelong anticoagulant therapy with vitamin K antagonists and constant monitoring of international normalised ratio. However, the optimal target range for international normalised ratio values remains poorly defined. Optimisation of the approaches to anticoagulant therapy for this category of patients is becoming increasingly important. This paper highlights the main problems and possible solutions for patients who have undergone implantation of mechanical heart valves and need constant intake of vitamin K antagonists.
- Open Access
- 8 December 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (11) , 5284
Russian consensus statement on the diagnosis and treatment of patients with carotid stenosis
Carotid stenosis is a multidisciplinary problem that requires the involvement of a specialists’ team, including cardiovascular surgeons, neurosurgeons, endovascular surgeons, cardiologists, neurologists, and internists. In this consensus statement, a group of experts considered the main stages of diagnosing carotid stenosis, as well as discussed, the necessary prevention methods and features of choosing the optimal treatment approach. The aim was to provide concise and structured information on the management of patients with carotid stenosis. This document was developed based on the updated clinical guidelines of the European Society for Vascular Surgery and the American Association for Vascular Surgery, taking into account the consensus opinion of Russian experts.
- 8 December 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (11) , 5284
Open AccessRussian consensus statement on the diagnosis and treatment of patients with carotid stenosis
Carotid stenosis is a multidisciplinary problem that requires the involvement of a specialists’ team, including cardiovascular surgeons, neurosurgeons, endovascular surgeons, cardiologists, neurologists, and internists. In this consensus statement, a group of experts considered the main stages of diagnosing carotid stenosis, as well as discussed, the necessary prevention methods and features of choosing the optimal treatment approach. The aim was to provide concise and structured information on the management of patients with carotid stenosis. This document was developed based on the updated clinical guidelines of the European Society for Vascular Surgery and the American Association for Vascular Surgery, taking into account the consensus opinion of Russian experts.
- Open Access
- 4 September 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (8) , 4565
Meshalkin National Medical Research Center
We present three cases of successful transatrial transcatheter valve-in-valve implantation in patients with bioprosthetic mitral valve dysfunction. Patients with a high surgical risk, with severe heart failure due to bioprosthetic mitral valve dysfunction, were implanted with transcatheter prostheses using the transatrial approach.Transesophageal echocardiography and fluoroscopy-guided transcatheter mitral prosthetic valve positioning was performed. With a cardiac pacing at 180 bpm, a transcatheter valve was implanted. The transcatheter valves functioned properly after surgery. The patients were discharged in satisfactory condition.
- 4 September 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (8) , 4565
Open AccessMeshalkin National Medical Research Center
We present three cases of successful transatrial transcatheter valve-in-valve implantation in patients with bioprosthetic mitral valve dysfunction. Patients with a high surgical risk, with severe heart failure due to bioprosthetic mitral valve dysfunction, were implanted with transcatheter prostheses using the transatrial approach.Transesophageal echocardiography and fluoroscopy-guided transcatheter mitral prosthetic valve positioning was performed. With a cardiac pacing at 180 bpm, a transcatheter valve was implanted. The transcatheter valves functioned properly after surgery. The patients were discharged in satisfactory condition.
- Open Access
- 28 June 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (2) , 19-26
Edge-to-edge mitral valve repair in the surgical treatment of hypertrophic cardiomyopathy
Septal myectomy is the method of choice for treating symptomatic left ventricular outlet obstruction in patients with hypertrophic cardiomyopathy who are resistant to drug therapy. An important role in persistence, residual obstruction, mitral valve abnormalities and anterior systolic mitral valve movement is systolic anterior motion. Several authors have reported the use of edge-to-edge mitral valve repair in addition to septal myectomy in patients with mild septal hypertrophy. We performed a literature review on the surgical treatment of obstructive hypertrophic cardiomyopathy—mitral valve repair using the edge-to-edge technique with septal myectomy. Four retrospective studies and three clinical cases were analysed. The data of patients who underwent mitral valve repair surgery using the edge-to-edge technique with septal myectomy and had satisfactory long-term clinical and hemodynamic results were studied. This treatment technique should be considered in cases of unexpressed hypertrophy when isolated limited myectomy is insufficient to eliminate the left ventricular outlet or when there is a hemodynamically significant mitral insufficiency caused by anterior systolic movement of the mitral valve that increases the need for intervention on interventricular hypertrophy of the associated disease. Septal defect, plastic mitral valve, surgically significant residual mitral regurgitation and high residual left ventricular outflow gradients in long-term follow-up are feasible, safe and effective for anterior systolic mitral valve movement. Received 28 September 2020. Revised 23 March 2021. Accepted 25 March 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. Ovchinnikova, A.N. Pivkin, I.I. DeminDrafting the article: S.A. Budagaev, A.V. AfanasyevCritical revision of the article: A.V. Bogachev-Prokophiev, D.A. AstapovFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, M.A. Ovchinnikova, A.N. Pivkin, D.A. Astapov, I.I. Demin
- 28 June 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (2) , 19-26
Open AccessEdge-to-edge mitral valve repair in the surgical treatment of hypertrophic cardiomyopathy
Septal myectomy is the method of choice for treating symptomatic left ventricular outlet obstruction in patients with hypertrophic cardiomyopathy who are resistant to drug therapy. An important role in persistence, residual obstruction, mitral valve abnormalities and anterior systolic mitral valve movement is systolic anterior motion. Several authors have reported the use of edge-to-edge mitral valve repair in addition to septal myectomy in patients with mild septal hypertrophy. We performed a literature review on the surgical treatment of obstructive hypertrophic cardiomyopathy—mitral valve repair using the edge-to-edge technique with septal myectomy. Four retrospective studies and three clinical cases were analysed. The data of patients who underwent mitral valve repair surgery using the edge-to-edge technique with septal myectomy and had satisfactory long-term clinical and hemodynamic results were studied. This treatment technique should be considered in cases of unexpressed hypertrophy when isolated limited myectomy is insufficient to eliminate the left ventricular outlet or when there is a hemodynamically significant mitral insufficiency caused by anterior systolic movement of the mitral valve that increases the need for intervention on interventricular hypertrophy of the associated disease. Septal defect, plastic mitral valve, surgically significant residual mitral regurgitation and high residual left ventricular outflow gradients in long-term follow-up are feasible, safe and effective for anterior systolic mitral valve movement. Received 28 September 2020. Revised 23 March 2021. Accepted 25 March 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. Ovchinnikova, A.N. Pivkin, I.I. DeminDrafting the article: S.A. Budagaev, A.V. AfanasyevCritical revision of the article: A.V. Bogachev-Prokophiev, D.A. AstapovFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, M.A. Ovchinnikova, A.N. Pivkin, D.A. Astapov, I.I. Demin
- Open Access
- 14 September 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (8) , 3847
First experience of transcatheter implantation of a Russian-made MedLab-CT prosthesis in a patient with dysfunction of biological mitral valve prosthesis
We present a case report of successful transcatheter implantation of a Russian-made cardiac valve prosthesis in a patient with dysfunction of biological mitral valve prosthesis (valve-in-valve). A patient aged 78 years with a high surgical risk and severe heart failure due to mitral valve bioprosthesis dysfunction is described. Fluoroscopyand transesophageal echocardiography-guided transapical implantation of a MedLab-CT prosthesis (23 mm) was made. When a heart rate of 180 beats per minute, a stent prosthesis was implanted. Transcatheter implant valve functioned properly after surgery. The patient was discharged in satisfactory condition.
- 14 September 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (8) , 3847
Open AccessFirst experience of transcatheter implantation of a Russian-made MedLab-CT prosthesis in a patient with dysfunction of biological mitral valve prosthesis
We present a case report of successful transcatheter implantation of a Russian-made cardiac valve prosthesis in a patient with dysfunction of biological mitral valve prosthesis (valve-in-valve). A patient aged 78 years with a high surgical risk and severe heart failure due to mitral valve bioprosthesis dysfunction is described. Fluoroscopyand transesophageal echocardiography-guided transapical implantation of a MedLab-CT prosthesis (23 mm) was made. When a heart rate of 180 beats per minute, a stent prosthesis was implanted. Transcatheter implant valve functioned properly after surgery. The patient was discharged in satisfactory condition.
- 9 May 2020
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 31 (2) , 158-165
Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
OBJECTIVES: There is very little evidence comparing the safety and efficacy of alcohol septal ablation versus septal myectomy for a septal reduction in patients with hypertrophic obstructive cardiomyopathy. This study aimed to compare the immediate and long-term outcomes of these procedures. METHODS: Following propensity score matching, we retrospectively analysed outcomes in 105 patients who underwent myectomy and 105 who underwent septal ablation between 2011 and 2017 at 2 reference centres. RESULTS: The mean age was 51.9 ± 14.3 and 52.2 ± 14.3 years in the myectomy and ablation groups, respectively (P = 0.855), and postoperative left ventricular outflow tract gradients were 13 (10–19) mmHg vs 16 (12–26) mmHg; P = 0.025. The 1-year prevalence of the New York Heart Association class III–IV was higher in the ablation group (none vs 6.4%; P = 0.041). The 5-year overall survival rate [96.8% (86.3–99.3) after myectomy and 93.5% (85.9–97.1) after ablation; P = 0.103] and cumulative incidence of sudden cardiac death [0% and 1.9% (0.5–7.5), respectively P = 0.797] did not differ between the groups. The cumulative reoperation rate within 5 years was lower after myectomy than after ablation [2.0% (0.5–7.6) vs 14.6% (8.6–24.1); P = 0.003]. Ablation was associated with a higher reoperation risk (subdistributional hazard ratio = 5.9; 95% confidence interval 1.3–26.3, P = 0.020). At follow-up, left ventricular outflow tract gradient [16 (11–20) vs 23 (15–59) mmHg; P < 0.001] and prevalence of 2+ mitral regurgitation (1.1% vs 10.6%; P = 0.016) were lower after myectomy than after ablation. CONCLUSIONS: Both procedures improved functional capacity; however, myectomy better-resolved classes III–IV of heart failure. Septal ablation was associated with higher reoperation rates. Myectomy demonstrated benefits in gradient relief and mitral regurgitation elimination. The results suggest that decreasing rates of myectomy procedures need to be investigated and reconsidered.
- 9 May 2020
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 31 (2) , 158-165
Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
OBJECTIVES: There is very little evidence comparing the safety and efficacy of alcohol septal ablation versus septal myectomy for a septal reduction in patients with hypertrophic obstructive cardiomyopathy. This study aimed to compare the immediate and long-term outcomes of these procedures. METHODS: Following propensity score matching, we retrospectively analysed outcomes in 105 patients who underwent myectomy and 105 who underwent septal ablation between 2011 and 2017 at 2 reference centres. RESULTS: The mean age was 51.9 ± 14.3 and 52.2 ± 14.3 years in the myectomy and ablation groups, respectively (P = 0.855), and postoperative left ventricular outflow tract gradients were 13 (10–19) mmHg vs 16 (12–26) mmHg; P = 0.025. The 1-year prevalence of the New York Heart Association class III–IV was higher in the ablation group (none vs 6.4%; P = 0.041). The 5-year overall survival rate [96.8% (86.3–99.3) after myectomy and 93.5% (85.9–97.1) after ablation; P = 0.103] and cumulative incidence of sudden cardiac death [0% and 1.9% (0.5–7.5), respectively P = 0.797] did not differ between the groups. The cumulative reoperation rate within 5 years was lower after myectomy than after ablation [2.0% (0.5–7.6) vs 14.6% (8.6–24.1); P = 0.003]. Ablation was associated with a higher reoperation risk (subdistributional hazard ratio = 5.9; 95% confidence interval 1.3–26.3, P = 0.020). At follow-up, left ventricular outflow tract gradient [16 (11–20) vs 23 (15–59) mmHg; P < 0.001] and prevalence of 2+ mitral regurgitation (1.1% vs 10.6%; P = 0.016) were lower after myectomy than after ablation. CONCLUSIONS: Both procedures improved functional capacity; however, myectomy better-resolved classes III–IV of heart failure. Septal ablation was associated with higher reoperation rates. Myectomy demonstrated benefits in gradient relief and mitral regurgitation elimination. The results suggest that decreasing rates of myectomy procedures need to be investigated and reconsidered.
- Open Access
- 11 July 2019
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 34 (2)
FLEXIBLE RINGS IN COMPARISON WITH RIGID RINGS IN THE TREATMENT OF FUNCTIONAL TRICUSPID INSUFFICIENCY: TWO DIFFERENT MODELS OF REVERSE REMODELING OF THE RIGHT HEART
Objective. To compare the models of reverse remodeling of the right heart after the tricuspid valve repair with rigid or flexible rings.Material and Methods. During the period from September, 2016 to February, 2018, 308 patients who had indications for intervention on the mitral valve and concomitant tricuspid insufficiency without significant differences in clinical status were randomized into two groups. Patients of both groups underwent intervention on the mitral valve with concomitant tricuspid valve repair by a rigid ring (Rigid group, n=154) or a flexible ring (Flex group, n=154)Results. The perioperative mortality rates were 2.0% in the Rigid group and 2.5% in the Flex group (p=0.504). There was no difference in the pacemaker implantation rate (5.1% vs. 2.6%, p=0.238). Freedom from tricuspid insufficiency recurrence at 12 months follow-up was comparable (96.7% in the Rigid group vs 96.1% in the Flex group, p=0.521). The global systolic function of the right ventricle (fractional change in area, FAC; ejection fraction, EF) significantly increased in both groups (pConclusion. Both types of the devises had low rates of recurrence of tricuspid insufficiency at the midterm follow-up and contributed to the restoration of the global systolic function of the right ventricle. However, the rigid rings due to their design fix the tricuspid valve annulus, which inevitably affects the regional systolic function. In perspective, the flexible rings can function without interfering with the restoration of the natural shape of the tricuspid valve annulus and its uniform contraction during the cardiac cycle, thus ensuring a significant increase in regional systolic function.
- 11 July 2019
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 34 (2)
Open AccessFLEXIBLE RINGS IN COMPARISON WITH RIGID RINGS IN THE TREATMENT OF FUNCTIONAL TRICUSPID INSUFFICIENCY: TWO DIFFERENT MODELS OF REVERSE REMODELING OF THE RIGHT HEART
Objective. To compare the models of reverse remodeling of the right heart after the tricuspid valve repair with rigid or flexible rings.Material and Methods. During the period from September, 2016 to February, 2018, 308 patients who had indications for intervention on the mitral valve and concomitant tricuspid insufficiency without significant differences in clinical status were randomized into two groups. Patients of both groups underwent intervention on the mitral valve with concomitant tricuspid valve repair by a rigid ring (Rigid group, n=154) or a flexible ring (Flex group, n=154)Results. The perioperative mortality rates were 2.0% in the Rigid group and 2.5% in the Flex group (p=0.504). There was no difference in the pacemaker implantation rate (5.1% vs. 2.6%, p=0.238). Freedom from tricuspid insufficiency recurrence at 12 months follow-up was comparable (96.7% in the Rigid group vs 96.1% in the Flex group, p=0.521). The global systolic function of the right ventricle (fractional change in area, FAC; ejection fraction, EF) significantly increased in both groups (pConclusion. Both types of the devises had low rates of recurrence of tricuspid insufficiency at the midterm follow-up and contributed to the restoration of the global systolic function of the right ventricle. However, the rigid rings due to their design fix the tricuspid valve annulus, which inevitably affects the regional systolic function. In perspective, the flexible rings can function without interfering with the restoration of the natural shape of the tricuspid valve annulus and its uniform contraction during the cardiac cycle, thus ensuring a significant increase in regional systolic function.